If you are living with psoriasis, you may know how much the condition can affect both your skin and your quality of life. Although treatments such as topical medicines, phototherapy and biologic therapies can be effective, you may still face challenges such as incomplete improvement, side effects or inconvenient treatment schedules.
The OLYMPIA 1 and OLYMPIA 2 phase III trials introduced deucravacitinib, a first-in-class selective TYK2 inhibitor that offers a new oral treatment option for moderate-to-severe plaque psoriasis. These studies were designed to assess how well the treatment works and how safe it is when compared with existing therapies.
Understanding the design and findings of these trials can help you appreciate why deucravacitinib has attracted so much interest in psoriasis care. The results are helping doctors, researchers and patients better understand where this treatment may fit into modern psoriasis management.
What Is Deucravacitinib?
Deucravacitinib is an oral medication that selectively blocks TYK2, a member of the Janus kinase (JAK) family. If you have moderate-to-severe plaque psoriasis, this treatment offers you a different way to target the inflammation that drives your condition.
By selectively inhibiting TYK2, deucravacitinib reduces signalling through IL-23, IL-12 and type I interferon pathways, which play important roles in the inflammatory processes involved in plaque psoriasis. This indirectly reduces downstream inflammatory activity, including pathways associated with IL-17.
Unlike broader JAK inhibitors, deucravacitinib is designed to work more selectively. For you, this may mean effective control of your psoriasis while potentially reducing the risk of some off-target side effects associated with less targeted treatments.
Rationale for the OLYMPIA Trials
The OLYMPIA trials were designed to evaluate the benefits of a selective oral TYK2 inhibitor for people with moderate-to-severe plaque psoriasis. If you are looking for new treatment options, these studies were created to determine whether deucravacitinib could give you effective and reliable control of your psoriasis.
The trials focused on key areas such as efficacy, safety and long-term tolerability. This information helps you understand not only how well the treatment may improve your symptoms, but also whether you could use it safely over an extended period.
By carrying out two large phase III studies, researchers were able to confirm their findings across different patient populations. For you, this provides greater confidence that the results are consistent and that the treatment may be suitable for a wide range of people living with psoriasis.
Evidence Note
The OLYMPIA 1 and OLYMPIA 2 studies are pivotal Phase III randomised clinical trials evaluating deucravacitinib in adults with moderate-to-severe plaque psoriasis. Conducted using rigorous double-blind study designs, these trials assessed both clinical effectiveness and safety over time. Their findings have contributed to the growing evidence supporting selective TYK2 inhibition as a targeted oral treatment option for appropriately selected patients with plaque psoriasis.
Study Design: OLYMPIA 1
OLYMPIA 1 was a randomised, double-blind, phase III trial that compared deucravacitinib with both placebo and an active comparator, apremilast. If you are interested in how new psoriasis treatments are assessed, this type of study design helps ensure that the results are reliable and unbiased.
The trial included adults with moderate-to-severe plaque psoriasis who met specific requirements for body surface area involvement and Psoriasis Area and Severity Index (PASI) scores. This meant that the treatment was tested in people whose psoriasis had a significant impact on their daily lives.
The primary goal of the study was to measure skin improvement using PASI 75 at week 16, which indicates a 75% reduction in psoriasis severity. Researchers also looked at patient-reported outcomes so you can better understand how the treatment may affect both your skin and your overall quality of life.
Study Design: OLYMPIA 2
OLYMPIA 2 used a study design that closely mirrored OLYMPIA 1 but included a separate group of participants to confirm whether the findings were consistent. If you are looking at the evidence behind deucravacitinib, this approach gives you greater confidence that the results are reliable and can be reproduced.
The trial compared deucravacitinib directly with placebo and used similar inclusion criteria and study endpoints. This allowed researchers to determine whether you could expect similar improvements in your psoriasis and whether the treatment maintained a consistent safety profile.
By repeating the methodology in a second large phase III trial, researchers strengthened the overall evidence supporting deucravacitinib. For you, this means there is more robust data showing that the treatment can provide effective and predictable results for people with moderate-to-severe plaque psoriasis.
OLYMPIA 1 vs OLYMPIA 2 at a Glance
| Feature | OLYMPIA 1 | OLYMPIA 2 |
| Phase | III | III |
| Design | Randomised, double-blind | Randomised, double-blind |
| Population | Moderate-to-severe plaque psoriasis | Moderate-to-severe plaque psoriasis |
| Comparator | Placebo + Apremilast | Placebo |
| Primary Endpoint | PASI 75 at Week 16 | PASI 75 at Week 16 |
| Follow-up | Week 52 | Week 52 |
Patient Population
Across both OLYMPIA trials, participants had been living with moderate-to-severe plaque psoriasis for at least six months. If you have been dealing with persistent psoriasis, you may recognise how significantly the condition can affect your daily life and wellbeing.
Most participants had previously used topical treatments, although their experience with systemic therapies varied. This allowed researchers to assess how deucravacitinib worked in people with different treatment histories, helping you better understand where the medication may fit into your own treatment journey.
The trials also included participants from a range of demographic backgrounds to improve the generalisability of the findings. For you, this means the results are more likely to reflect how the treatment may perform in a broad and diverse population of people living with psoriasis.
Quality of Life Outcomes
Patients treated with deucravacitinib reported improvements in their Dermatology Life Quality Index (DLQI) scores, reflecting less physical discomfort and better emotional wellbeing. If psoriasis affects your confidence or daily activities, these findings suggest that treatment may improve more than just your skin.
Many participants also experienced better day-to-day functioning and felt more comfortable in social situations. For you, this could mean feeling less self-conscious about your psoriasis and having greater confidence in work, relationships and everyday life.
These results show that the benefits of deucravacitinib extend beyond achieving clearer skin. They highlight how effective treatment can make a meaningful difference to your overall quality of life and wellbeing.
Dosing Regimen
In the OLYMPIA trials, deucravacitinib was taken orally once a day at a fixed dose. If you prefer a straightforward treatment routine, this simple dosing schedule may be easier to fit into your daily life.
The once-daily tablet offers a convenient alternative to injectable biologic treatments that may require regular clinic visits or injections. For you, this could mean greater flexibility and less disruption to your normal routine.
Oral treatment may also improve adherence and overall satisfaction with therapy. If you find complex treatment schedules difficult to maintain, a simple once-daily medication may help you stay consistent with your psoriasis treatment plan.
Primary Endpoint: PASI 75
PASI 75 refers to a 75% reduction in psoriasis severity compared with the start of treatment. If you have moderate-to-severe plaque psoriasis, reaching PASI 75 would usually mean a significant improvement in your skin and a noticeable reduction in your symptoms.
This measure is widely used in psoriasis studies because it helps doctors understand whether a treatment is providing meaningful clinical benefits. For you, achieving PASI 75 may translate into less redness, scaling and discomfort, which can make a real difference to your daily life.
The OLYMPIA trials used PASI 75 at week 16 as the primary endpoint to assess the effectiveness of deucravacitinib. By using this recognised measure, researchers could determine how well the treatment improved psoriasis during the early stages of therapy.
Secondary Endpoints
The OLYMPIA trials also assessed several secondary endpoints to provide a broader understanding of how well deucravacitinib worked. These included PASI 90 and PASI 100, which measure near-complete and complete skin clearance and can help you understand the potential for more substantial improvements in your psoriasis.
Researchers also evaluated patient-reported outcomes using the Dermatology Life Quality Index (DLQI). If psoriasis affects your confidence, relationships or daily activities, these measures help show whether treatment can improve your quality of life as well as your skin symptoms.
Safety and tolerability were also important parts of the secondary analyses. For you, this information is valuable because it helps determine not only how effective the treatment may be, but also whether it can be used comfortably and safely over time.
Key Findings: Efficacy at Week 16
At week 16, deucravacitinib achieved significantly higher PASI 75 response rates than placebo in both OLYMPIA trials. If you are looking for an effective treatment option, these findings suggest that the medication can produce meaningful improvements within a relatively short period.
Many participants also achieved PASI 90 and PASI 100, meaning they experienced near-complete or complete skin clearance. For you, this level of improvement could translate into fewer symptoms and a noticeable improvement in the appearance of your skin.
These results highlight the ability of deucravacitinib to deliver substantial clinical benefits in a matter of months. They also suggest that you may experience significant improvements in both your psoriasis severity and your overall quality of life with treatment.
In both OLYMPIA trials, significantly more patients receiving deucravacitinib achieved PASI 75 at Week 16 than those receiving placebo. Higher proportions also achieved PASI 90 and complete or near-complete skin clearance, while quality-of-life scores measured using the Dermatology Life Quality Index (DLQI) improved significantly. These consistent findings across both studies strengthened confidence in deucravacitinib as an effective oral treatment for moderate-to-severe plaque psoriasis.
Comparison With Apremilast
In OLYMPIA 1, deucravacitinib achieved higher PASI 75 and PASI 90 response rates than apremilast. If you are considering an oral treatment for moderate-to-severe plaque psoriasis, these results suggest that deucravacitinib may give you greater improvements in your skin symptoms.
The selective TYK2 inhibitor also showed a faster onset of improvement across several measures. For you, this could mean noticing positive changes in your psoriasis sooner, which may help you feel more confident about your treatment journey.
These findings position deucravacitinib as an important alternative for people considering oral systemic therapy. If you are looking for an effective oral option, the results suggest that this treatment may offer you both convenience and meaningful clinical benefits.
Key Clinical Findings from the OLYMPIA Programme
| Outcome | Overall Finding |
| PASI 75 | Significantly higher response than placebo |
| PASI 90 | Higher rates of near-complete skin clearance |
| PASI 100 | More patients achieved complete skin clearance |
| DLQI | Significant improvement in quality of life |
| Safety | Generally well tolerated |
| Serious adverse events | Rare |
| Treatment adherence | High throughout the study |
Onset of Action
Many patients treated with deucravacitinib experienced visible improvements in their psoriasis within the first few weeks of therapy. If you are starting a new treatment, seeing early changes in your skin can be encouraging and may give you greater confidence in the medication.
An early response can also improve treatment adherence and overall satisfaction, particularly with oral therapies. For you, noticing improvements quickly may make it easier to stay committed to your treatment plan and continue taking your medication as prescribed.
Rapid improvement is clinically important because ongoing inflammation can affect both your quality of life and your long-term health. By reducing inflammation sooner, effective treatment may help you feel better physically and emotionally while potentially lowering the impact of psoriasis-related complications.
Oral vs Injectable Treatments
Deucravacitinib offers the convenience of an oral treatment while achieving levels of effectiveness that are comparable to some injectable biologic therapies. If you prefer taking a tablet rather than having injections, this option may fit more easily into your daily routine.
For some people, an oral medication can improve treatment adherence and make long-term therapy feel more manageable. If you find injections inconvenient or difficult, an effective oral treatment may encourage you to stay consistent with your psoriasis management plan.
The availability of oral options also expands the range of treatments available for psoriasis. This gives you and your clinician more flexibility to choose a therapy that matches your preferences, lifestyle and individual treatment needs.
Long-Term Efficacy
Follow-up data from the OLYMPIA trials suggested that the benefits of deucravacitinib were maintained through week 52. If you are considering long-term treatment for psoriasis, these findings indicate that the improvements seen early in therapy may continue over time.
Participants maintained both skin clearance and improvements in quality of life during extended follow-up. For you, this could mean more consistent control of your symptoms and a reduced impact of psoriasis on your daily activities and wellbeing.
Consistency of effect is particularly important because psoriasis is a long-term condition that often requires ongoing management. A treatment that continues to work over time may help you maintain clearer skin and improve your confidence in managing your condition.
Research Insight: Deucravacitinib represents a different approach from traditional Janus kinase (JAK) inhibitors because it selectively binds to the regulatory domain of TYK2 rather than the catalytic domain. This targeted mechanism is designed to maintain clinical effectiveness while reducing some of the off-target effects associated with broader JAK inhibition, although ongoing long-term real-world data continue to evaluate its safety profile.
Safety Profile
Deucravacitinib was generally well tolerated in the OLYMPIA trials, with most side effects being mild to moderate in severity. If you are considering this treatment, these findings may reassure you that the medication was well accepted by many people with moderate-to-severe plaque psoriasis.
The most commonly reported side effects included nasopharyngitis, headache and upper respiratory tract infections. For you, it is important to know that these events were usually manageable and did not raise major safety concerns during the studies.
Importantly, no unexpected safety signals emerged and Serious adverse events were uncommon during the clinical trials. This suggests that deucravacitinib may offer you effective psoriasis control while maintaining a favourable safety profile over the course of treatment.
Laboratory Monitoring
Unlike broader JAK inhibitors, deucravacitinib selectively targets TYK2, which reduces the need for intensive laboratory monitoring. If you are considering long-term treatment, this may make the medication more convenient and easier to manage.
Routine blood tests may still be recommended during treatment to help ensure your ongoing safety. For you, these checks can provide reassurance that the medication continues to be used appropriately and that any potential issues are identified early.
This reduced monitoring requirement is an important advantage compared with some systemic immunosuppressive treatments. It may simplify your treatment journey and lessen the burden of frequent testing while still allowing your clinician to monitor your overall health.
Clinical Tip: Although deucravacitinib is taken as a tablet, it remains a prescription systemic therapy. Before treatment begins, your dermatologist will consider factors such as previous psoriasis treatments, infection history, vaccination status, pregnancy planning and any other medical conditions to ensure the medicine is appropriate for you.
Cardiovascular Considerations
No significant increase in cardiovascular events was reported with deucravacitinib compared with placebo in the OLYMPIA trials. If you are concerned about the long-term safety of systemic treatments, these findings may provide some reassurance about the medication’s cardiovascular profile.
This is particularly important because some immunomodulatory treatments can be associated with cardiovascular risks. For you, understanding these safety considerations can help when discussing the potential benefits and risks of treatment with your clinician.
Monitoring is still recommended, especially if you have existing health conditions or other cardiovascular risk factors. Regular follow-up can help ensure that your treatment remains both effective and appropriate for your overall health needs.
Infection Risk
Infections were uncommon in the OLYMPIA trials and, when they did occur, they were generally mild. If you are concerned about the risk of infections while taking an immune-modifying treatment, these findings may provide some reassurance.
Importantly, there was no increase in opportunistic infections among participants receiving deucravacitinib. For you, this suggests that the treatment did not appear to cause the higher rates of serious infections sometimes associated with broader immunosuppressive therapies.
This safety profile is particularly encouraging for people who are worried about the effects of long-term immune modulation. However, your clinician will still monitor your health and discuss any individual risk factors before and during treatment.
Laboratory Abnormalities
Laboratory abnormalities reported during the OLYMPIA trials were generally minimal and temporary. If you are considering deucravacitinib, these findings may reassure you that the treatment was not linked to major changes in routine blood test results.
No clinically significant changes in liver function or blood counts were reported during the studies. For you, this suggests that the medication demonstrated a favourable laboratory safety profile and did not appear to cause important abnormalities in these areas.
This is particularly beneficial because it may reduce the need for frequent laboratory monitoring compared with some other systemic treatments. For you, a simpler monitoring schedule could make long-term treatment more convenient while still allowing your clinician to monitor your health appropriately.
Treatment Discontinuation
Only a small number of patients stopped treatment because of adverse events during the OLYMPIA trials. If you are considering deucravacitinib, these findings suggest that most people were able to continue treatment without significant difficulties.
The majority of participants tolerated the medication well throughout the study period. For you, this is important because long-term treatment is often needed to manage a chronic condition such as psoriasis effectively.
These results support the practicality of using deucravacitinib as a long-term oral therapy in real-world care. A treatment that is both effective and well tolerated may make it easier for you to remain consistent with your psoriasis management plan.
Implications for Clinical Practice
The OLYMPIA trials showed that selective TYK2 inhibition can provide an effective and generally well-tolerated oral treatment for moderate-to-severe plaque psoriasis. If you are exploring your treatment options, these findings suggest that deucravacitinib may be a valuable addition to current psoriasis therapies.
For some people, an oral medication may be more appealing than injectable treatments. If you prefer a tablet-based approach, deucravacitinib may offer you a convenient alternative while still providing meaningful improvements in your skin symptoms and quality of life.
When choosing the most suitable treatment, your clinician will consider factors such as your preferences, other health conditions and previous treatment experiences. This personalised approach helps ensure that you receive a therapy that fits both your medical needs and your lifestyle.
Rapid Improvement and Patient Satisfaction
The early onset of improvement seen with deucravacitinib can have an important effect on patient satisfaction. If you notice visible changes in your skin soon after starting treatment, you may feel more confident that the medication is working.
People who see benefits quickly are often more likely to continue taking their treatment as prescribed. For you, early improvement may make it easier to stay committed to your treatment plan and maintain long-term control of your psoriasis.
This is particularly important because psoriasis is a chronic condition that can significantly affect your quality of life. A treatment that delivers noticeable results early may help improve both your symptoms and your overall wellbeing.
Considerations in Special Populations
The OLYMPIA trials included participants from a range of backgrounds, helping researchers understand how deucravacitinib performs in a diverse population. However, if you have multiple health conditions, are older, or have previously used biologic therapies, further research may provide additional information that is more specific to your situation.
Monitoring remains important if you have pre-existing medical conditions or other factors that could influence your treatment response. For you, regular follow-up appointments can help ensure that the medication continues to be both safe and effective.
Future studies are expected to provide a clearer understanding of how deucravacitinib can be used in a broader range of patients. This ongoing research may help you and your clinician make more informed treatment decisions in the years ahead.
Cost and Accessibility Considerations
As a newer oral therapy, the cost of deucravacitinib and the availability of insurance or healthcare coverage may affect access to treatment. If you are considering this medication, practical factors such as affordability can play an important role in your decision.
Comparing deucravacitinib with existing biologic and oral treatments can help you and your clinician decide which option is most suitable for your needs. The choice of treatment often involves balancing effectiveness, convenience and long-term costs.
Affordability and adherence should also be considered when planning your treatment. For you, a therapy that is both accessible and manageable over the long term may improve your ability to stay consistent with treatment and achieve better outcomes.
Overall Impact on Psoriasis Care
Deucravacitinib represents an important advance in oral systemic therapy for psoriasis. If you are looking for a treatment that combines effectiveness with the convenience of a tablet, this medication offers a new option in the management of moderate-to-severe plaque psoriasis.
Its combination of clinical efficacy, favourable safety data and simple oral administration may help improve both treatment outcomes and quality of life. For you, this could mean better control of your symptoms while making long-term treatment easier to manage.
The OLYMPIA trials provide strong evidence to support the use of deucravacitinib in suitable patients. These findings may encourage wider adoption of the treatment and give you and your clinician another valuable option when planning your psoriasis care.
Clinical Practice Note: Modern psoriasis treatment aims not only to improve visible plaques but also to reduce the overall burden of disease on physical wellbeing, mental health and quality of life. When choosing systemic treatment, dermatologists consider disease severity, previous treatment response, co-existing medical conditions and your personal preferences to develop an individualised management plan.
Future Research Directions
Further research is needed to better understand the long-term role of deucravacitinib in psoriasis management. If you are considering this treatment, future studies on long-term safety, real-world effectiveness and comparisons with other systemic therapies may provide even clearer guidance.
Ongoing research may also explore whether deucravacitinib can be used alongside other treatments and how it should be introduced within different treatment pathways. For you, these studies could help identify the most effective way to use the medication based on your individual needs.
Continued research will also support the development of more personalised treatment strategies for psoriasis. As new evidence emerges, you and your clinician may have more opportunities to tailor treatment choices and achieve better long-term outcomes.
Patient Education and Expectations
Patient education is an important part of successful psoriasis treatment. If you understand what to expect from your medication, including the likely timeline for improvement and possible side effects, you may feel more confident and prepared during your treatment journey.
It is also important to recognise that the maximum benefits of treatment, including significant skin clearance, may take several weeks or even months to develop. For you, having realistic expectations can help prevent disappointment and encourage you to continue treatment as advised.
Active involvement in your care can improve both treatment adherence and overall satisfaction. When you understand your treatment plan and feel engaged in decision-making, you may be more likely to remain committed to long-term psoriasis management.
Deucravacitinib should only be started under the supervision of a dermatologist experienced in managing moderate-to-severe psoriasis. Regular follow-up appointments help assess treatment response, monitor any adverse effects and ensure that therapy remains appropriate over time.
Role in Personalized Therapy
Deucravacitinib adds another option to the personalised approach to psoriasis treatment. If you are living with moderate-to-severe psoriasis, having a wider range of therapies available means your treatment can be tailored more closely to your individual needs.
Clinicians can consider factors such as the severity of your psoriasis, any other health conditions you may have and whether you prefer an oral medication or an injectable treatment. For you, this personalised approach may help identify a therapy that fits both your medical needs and your lifestyle.
Shared decision-making is also an important part of modern psoriasis care. When you are involved in treatment decisions and understand your options, you may feel more confident in your care and achieve better long-term outcomes.
Long-Term Safety Monitoring
Ongoing monitoring remains an important part of treatment with deucravacitinib. If you are taking a long-term immunomodulatory therapy, regular follow-up appointments can help identify any adverse events at an early stage and ensure that your treatment remains appropriate.
Real-world studies will continue to provide valuable information about the long-term tolerability and safety of the medication. For you, these findings may offer greater reassurance about how the treatment performs outside of clinical trials and in everyday practice.
This type of monitoring is a standard part of care for chronic immunomodulatory therapies. It helps you and your clinician balance the benefits of treatment with ongoing safety considerations throughout your psoriasis management journey.
Summary of Clinical Significance
The OLYMPIA trials showed that deucravacitinib is an effective and generally well-tolerated oral treatment for moderate-to-severe plaque psoriasis. If you are exploring new treatment options, these findings suggest that the medication can provide meaningful improvements in both skin symptoms and quality of life.
The studies also demonstrated that deucravacitinib can deliver relatively rapid improvements and maintain its benefits over time with a convenient once-daily dosing schedule. For you, this combination of effectiveness and simplicity may make long-term treatment easier to manage.
These results provide patients and clinicians with an important new option in psoriasis care. As treatment choices continue to expand, you may have more opportunities to find a therapy that suits your individual needs and treatment preferences.
Key Takeaways:
- The OLYMPIA 1 and OLYMPIA 2 trials demonstrated that deucravacitinib is an effective oral treatment for moderate-to-severe plaque psoriasis.
- Deucravacitinib is the first selective TYK2 inhibitor approved for plaque psoriasis.
- Many participants achieved significant skin clearance and improved quality of life.
- The treatment showed a favourable safety profile during the clinical trials.
- Once-daily oral dosing offers an alternative to injectable biologic therapies for appropriate patients.
- Treatment decisions should always be individualised in consultation with a dermatologist.
Myth vs Fact: The OLYMPIA Trials and Deucravacitinib
| Myth | Fact |
| Oral psoriasis medicines are always less effective than biologic injections. | Newer targeted oral treatments such as deucravacitinib demonstrated strong efficacy in large Phase III clinical trials. |
| PASI 75 means psoriasis has completely disappeared. | PASI 75 represents a 75% improvement from baseline rather than complete clearance. |
| Everyone responds to deucravacitinib in the same way. | Individual treatment responses vary depending on disease severity, previous therapies and personal health factors. |
| Once the skin improves, treatment can always be stopped. | Psoriasis is a chronic condition and ongoing management is often required to maintain disease control. |
| Deucravacitinib removes the need for follow-up appointments. | Regular clinical review remains important to monitor treatment effectiveness and safety. |
FAQs:
1. What were the OLYMPIA 1 and OLYMPIA 2 trials?
The OLYMPIA 1 and OLYMPIA 2 trials were large phase III clinical studies designed to evaluate the effectiveness and safety of deucravacitinib in adults with moderate-to-severe plaque psoriasis. The trials compared deucravacitinib with placebo, and OLYMPIA 1 also included a comparison with apremilast to assess how the treatment performed against an established oral psoriasis therapy.
2. What is deucravacitinib and how does it work?
Deucravacitinib is an oral selective TYK2 inhibitor used to treat moderate-to-severe plaque psoriasis. It works by blocking TYK2, a protein involved in immune pathways such as IL-23 signalling, which plays an important role in the inflammation that causes psoriasis symptoms.
3. How effective was deucravacitinib in the OLYMPIA trials?
The OLYMPIA trials showed that deucravacitinib significantly improved psoriasis severity compared with placebo. Many participants achieved PASI 75, PASI 90 and PASI 100 responses, meaning they experienced substantial reductions in psoriasis symptoms, including near-complete or complete skin clearance.
4. How quickly does deucravacitinib start working for psoriasis?
Some people in the OLYMPIA trials experienced noticeable improvements within the first few weeks of treatment. However, the full benefits of deucravacitinib may take several weeks or months to develop, and continued treatment is usually needed to maintain improvement.
5. How is deucravacitinib different from biologic treatments for psoriasis?
Deucravacitinib is taken as a once-daily oral tablet, while many biologic treatments are given by injection. Its oral dosing may offer greater convenience for people who prefer tablets, while still providing significant improvements in psoriasis symptoms.
6. Was deucravacitinib more effective than apremilast?
In the OLYMPIA 1 trial, deucravacitinib produced higher PASI 75 and PASI 90 response rates than apremilast. The findings suggested that deucravacitinib may provide greater skin improvement for people who require an effective oral treatment option.
7. What side effects were reported with deucravacitinib?
In the OLYMPIA trials, deucravacitinib was generally well tolerated. The most commonly reported side effects included nasopharyngitis, headache and upper respiratory tract infections, with most events being mild to moderate in severity.
8. Does treatment with deucravacitinib require regular blood monitoring?
Deucravacitinib’s selective action on TYK2 means it may require less intensive laboratory monitoring compared with some broader immunosuppressive treatments. However, your dermatologist may still recommend routine checks and follow-up appointments to monitor your overall health and treatment response.
9. Can deucravacitinib provide long-term control of psoriasis?
Follow-up results from the OLYMPIA trials showed that improvements achieved with deucravacitinib could be maintained through longer-term treatment periods. Ongoing real-world studies will continue to provide more information about its long-term effectiveness and safety.
10. Who may benefit from deucravacitinib treatment?
Deucravacitinib may be considered for adults with moderate-to-severe plaque psoriasis who need systemic treatment. The most suitable treatment choice depends on factors such as psoriasis severity, previous treatments, other health conditions and personal preferences, so decisions should be made with guidance from a dermatologist.
Final Thoughts: The Future of Psoriasis Treatment with Deucravacitinib
The OLYMPIA 1 and OLYMPIA 2 trials have highlighted the potential of deucravacitinib as an important addition to modern psoriasis care. By offering a once-daily oral treatment with strong clinical results and a favourable safety profile, this therapy provides another option for people living with moderate-to-severe plaque psoriasis.
As psoriasis treatment continues to evolve, personalised care remains essential. The most suitable approach depends on your symptoms, treatment history, lifestyle preferences and overall health. Working closely with a dermatologist can help you understand which therapies may provide the best balance between effectiveness, convenience and long-term safety. If you’re considering finding the right support through a Psoriasis Clinic in London, you can get in touch with us at London Dermatology Centre.
References:
- National Institute for Health and Care Excellence (2023) Deucravacitinib for treating moderate to severe plaque psoriasis. Technology appraisal guidance TA907. Available at: https://www.nice.org.uk/guidance/ta907
- Armstrong, A.W., Gooderham, M., Warren, R.B. et al. (2023) ‘Deucravacitinib versus placebo and apremilast in moderate-to-severe plaque psoriasis: Efficacy and safety results from the 52-week, randomised, double-blinded, placebo-controlled phase III POETYK PSO-1 trial’, Journal of the American Academy of Dermatology, 88(1), pp.29–39. Available at: https://www.sciencedirect.com/science/article/pii/S0190962222022563
- Blauvelt, A. et al. (2024) ‘Deucravacitinib efficacy in scalp psoriasis: Pooled results from the phase III POETYK PSO-1 and PSO-2 trials’, Journal of the American Academy of Dermatology. Available at: https://www.sciencedirect.com/science/article/pii/S0190962223033741
- Kingston, P., Sadowski, D. and Stone, J. (2023) ‘Deucravacitinib: A novel TYK2 inhibitor for the treatment of plaque psoriasis’, Annals of Pharmacotherapy. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10768812/
- Armstrong, A.W. et al. (2025) ‘Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the phase III POETYK PSO-1, PSO-2 and long-term extension trials’, Journal of the European Academy of Dermatology and Venereology. Available at: https://pubmed.ncbi.nlm.nih.gov/40045918/